

Mathym closes its second financing round

The proceeds will be used to implement Mathym's first manufacturing line and conduct its two main R&D programs for dental applications

Champagne-Au-Mont-d'Or, October 13 2016 – Mathym SAS, a company specialized in the development, manufacturing and commercialization of colloids dedicated to biomedical applications announces today the completion of its €2.2 million second financing round.

This funding was led by an investment syndicate comprising historical investors OCTALFA, a family structure dedicated to the management and funding of innovative companies, and Rhône-Alpes Création, a regional seed fund specialized in technology companies, joined by Innovation Fund, a Belgian investment fund active in the field of chemistry and life sciences, Ravenala Sàrl, an investment structure founded by Alain Tornier, and Patrick Lermusiaux.

A significant part of the proceeds will be used by Mathym to implement its manufacturing line of ytterbium fluoride (YbF_3) colloidal solution. YbF_3 is used as a radiopacifier in dental and orthopedic materials formulation. Mathym is the first company to develop and market a liquid YbF_3 nanomaterial (YbF_3 colloidal solution) addressing all the dental industry needs and allowing not to use nanopowders which are considered as hazardous and hard-to-handle materials. The manufacturing line of YbF_3 will be implemented in early 2017 on Mathym new site at Champagne-Au-Mont-D'Or, north of Lyon, and commercialization will begin in Q2 2017.

“We would like to thank all the investors for their trust and support in Mathym”, said Julien Alberici, CEO of Mathym. “Our strategy is based on integrated R&D efforts validated through long-term partnerships with industrial players. The implementation of our first manufacturing line of nanomaterials is an exciting step forward for the company”.

This second financing of Mathym will also be used to complete two major R&D programs led by Mathym within the dental industry. “Our R&D department is currently focusing its efforts on obtaining remineralizing colloidal solutions to be used on teeth enamel” stated Frédéric Chaput, CSO of Mathym.

“We have been impressed by the first development milestones reached by Mathym and are delighted to contribute to the set-up of a company that is developing, manufacturing and commercializing innovative nanomaterials” commented François Cornelis, Chairman of Innovation Fund. “We believe in the strategy to build a biomedical-dedicated nanomaterials company. This is the best way to generate innovation, value and success based on scientific expertise and long-term partnerships”, concluded Gilles Alberici, Chairman of OCTALFA.

About Mathym

Mathym is a nanotechnology company specialized in the development, manufacturing and commercialization of innovative colloidal solutions dedicated to biomedical applications. Mathym emerged from academic research based at Lyon University and benefits from strong and exclusive industrial property. The company was set-up in September 2013 by Julien Alberici and Frederic Chaput, and first funded in 2014 by OCTALFA, Rhône-Alpes Création and Pertinence Invest. Mathym currently employs 10 people.

For more information: www.mathym.com

Contact: Julien Alberici, CEO, julien.alberici@mathym.com

About OCTALFA

OCTALFA is a family structure dedicated to the management and funding of innovative companies in healthcare. Since its inception, 14 innovative companies have been supported by OCTALFA. OCTALFA is part of initiative OCTALFA, a group committed to innovation and solidarity whose mission is twofold: to facilitate innovation and provide support to vulnerable people. OTONNALE, start-up incubator, the corporate foundation "Fondation Dominique & Tom Alberici – OCTALFA" and the endowment fund "Institut Dominique & Tom Alberici" complete initiative OCTALFA.

For more information: www.initiative-octalfa.eu

Contact: Gilles Alberici, Chairman, gilles.alberici@octalfa.eu

About Innovation Fund

The innovation Fund sa/nv invests in innovative start-ups and companies active in the field of chemistry and life sciences. It has been created in February 2015 and has a capital of €20 million. In October 2016, the fund has already invested in 7 companies.

For more information: www.innovationfund.eu

Contact: Pol-Henry Bonte, General Manager, phb@innovationfund.eu

About Rhône-Alpes Création

Since its launch in 1990, Rhône-Alpes Création has funded more than 275 ventures, investing in order to finance their first development stages. With €69 million under management thanks to Région Auvergne Rhône-Alpes, Bpifrance, industrial groups and regional banks, Rhône-Alpes Création stands as a major actor in the process of financing early stage ventures. It manages a 60-company portfolio with a team of 9 investors.

For more information: www.r-a-c.fr

Contact : Isabelle Bou Antoun, CEO, i.bouantoun@r-a-c.fr